Evaluation of the antileishmanial effect of polyclonal antibodies and cationic antimicrobial peptides.

IF 4.9 4区 医学 Q1 PARASITOLOGY Pathogens and Global Health Pub Date : 2023-06-01 DOI:10.1080/20477724.2022.2101838
Mahsa Esmaeilifallah, Hossein Khanahmad, Zahra Ghayour, Sedighe Saberi, Reza Kalantari, Seyed Hossein Hejazi
{"title":"Evaluation of the antileishmanial effect of polyclonal antibodies and cationic antimicrobial peptides.","authors":"Mahsa Esmaeilifallah,&nbsp;Hossein Khanahmad,&nbsp;Zahra Ghayour,&nbsp;Sedighe Saberi,&nbsp;Reza Kalantari,&nbsp;Seyed Hossein Hejazi","doi":"10.1080/20477724.2022.2101838","DOIUrl":null,"url":null,"abstract":"<p><p>Leishmaniasis is one of the tropical and subtropical diseases which, according to WHO, has the priority of control. The list of anti-leishmanial drugs is limited and requires side effects, high costs, and long-term treatments. Various species, parasite resistance, and simultaneous diseases are among the factors that affect the effectiveness of treatment. Due to these problems and based on satisfactory records of previous studies using antimicrobial peptides (AMPs) against infectious diseases, this study aimed to evaluate the antileishmanial effect of <i>Leishmania</i>-infected macrophage polyclonal antibody (LIMPA) with or without different concentrations (2, 4, 6, 8, 10, 20, 40, 60, and 100 µg/ml) of CM11 and (40, 80, and 100 µg/ml) BufIIIb, two AMPs, <i>in vitro</i> and their therapeutic effects against CL of Balb/c mice. Results showed that LIMPA induced an anti-proliferative effect on <i>Leishmania major</i> growth in macrophages <i>in vitro</i> and intramacrophage-amastigotes <i>in vivo</i>. CM11 with IC50 of 8.73 and 10.10 μg/ml at 48 hours, and BufIIIb with IC50 of 66.83 and 80.26 μg/ml, at 24 hours showed the most significant inhibition of <i>L. major</i> promastigotes and amastigotes. In addition, the CM11 and BufIIIb, with a CC50 of 9.7 μg/ml and 40.34 μg/ml, showed the most significant inhibition effect on the J774.A1 cell line at 48 hours, respectively. In addition, <i>in vivo</i> experiments using LIMPA with a 0.01 mg/kg dosage showed a significant difference (<i>p</i> < 0.001) in the last week of the measurement compared to the control. The results of this study may be a promising prospect for further investigations.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177747/pdf/YPGH_117_2101838.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/20477724.2022.2101838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Leishmaniasis is one of the tropical and subtropical diseases which, according to WHO, has the priority of control. The list of anti-leishmanial drugs is limited and requires side effects, high costs, and long-term treatments. Various species, parasite resistance, and simultaneous diseases are among the factors that affect the effectiveness of treatment. Due to these problems and based on satisfactory records of previous studies using antimicrobial peptides (AMPs) against infectious diseases, this study aimed to evaluate the antileishmanial effect of Leishmania-infected macrophage polyclonal antibody (LIMPA) with or without different concentrations (2, 4, 6, 8, 10, 20, 40, 60, and 100 µg/ml) of CM11 and (40, 80, and 100 µg/ml) BufIIIb, two AMPs, in vitro and their therapeutic effects against CL of Balb/c mice. Results showed that LIMPA induced an anti-proliferative effect on Leishmania major growth in macrophages in vitro and intramacrophage-amastigotes in vivo. CM11 with IC50 of 8.73 and 10.10 μg/ml at 48 hours, and BufIIIb with IC50 of 66.83 and 80.26 μg/ml, at 24 hours showed the most significant inhibition of L. major promastigotes and amastigotes. In addition, the CM11 and BufIIIb, with a CC50 of 9.7 μg/ml and 40.34 μg/ml, showed the most significant inhibition effect on the J774.A1 cell line at 48 hours, respectively. In addition, in vivo experiments using LIMPA with a 0.01 mg/kg dosage showed a significant difference (p < 0.001) in the last week of the measurement compared to the control. The results of this study may be a promising prospect for further investigations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多克隆抗体和阳离子抗菌肽抗利什曼原虫作用的评价。
利什曼病是世界卫生组织优先控制的热带和亚热带疾病之一。抗利什曼病药物的清单是有限的,并且需要副作用、高成本和长期治疗。影响治疗效果的因素包括各种物种、寄生虫耐药性和同时发生的疾病。鉴于这些问题,并基于以往抗菌肽(AMPs)抗感染性疾病研究的满意记录,本研究旨在评价不同浓度(2、4、6、8、10、20、40、60和100µg/ml) CM11和(40、80和100µg/ml) BufIIIb(两种抗菌肽)的体外抗利什曼感染巨噬细胞多克隆抗体(LIMPA)的抗利什曼效应及其对Balb/c小鼠CL的治疗作用。结果表明,LIMPA在体外对巨噬细胞和体内巨噬-无尾线虫的利什曼原虫生长具有抑制增殖作用。CM11在48 h的IC50分别为8.73和10.10 μg/ml, BufIIIb在24 h的IC50分别为66.83和80.26 μg/ml,对L. major promastigotes和amastigotes的抑制作用最为显著。此外,CM11和BufIIIb对J774的抑制作用最为显著,CC50分别为9.7 μg/ml和40.34 μg/ml。A1细胞系分别在48小时。此外,在体内实验中,0.01 mg/kg剂量的LIMPA具有显著差异(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pathogens and Global Health
Pathogens and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-PARASITOLOGY
CiteScore
6.00
自引率
0.00%
发文量
60
审稿时长
6-12 weeks
期刊介绍: Pathogens and Global Health is a journal of infectious disease and public health that focuses on the translation of molecular, immunological, genomics and epidemiological knowledge into control measures for global health threat. The journal publishes original innovative research papers, reviews articles and interviews policy makers and opinion leaders on health subjects of international relevance. It provides a forum for scientific, ethical and political discussion of new innovative solutions for controlling and eradicating infectious diseases, with particular emphasis on those diseases affecting the poorest regions of the world.
期刊最新文献
Hepatic schistosomiasis as a determining factor in the development of hepatic granulomas and liver fibrosis: a review of the current literature. Genetic diversity, variation and recombination among the human papillomaviruses (HPVs) genomes isolated in China: a comparative genomic and phylogenetic analysis The first molecular record of Borrelia afzelii, B. garinii, B. valaisiana, B. burgdorferi s.s. and B. bavariensis in Bosnia and Herzegovina Prevalence of Bordetella pertussis among children aged 4 years and above presenting with acute respiratory tract infection: a cross-sectional study. A review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1